New and Pipeline Antibiotics for Gram-Negative Bacterial Infections

NOTE: This session is part of the Live Intensive Studies and Clinical Sessions packages. All attendees may attend these thought-provoking and highly educational sessions. However, if you are board-certified, you must purchase the package(s) for your specialty to receive the recertification assessment and claim the recertification credit.

Antibiotic resistance has increasingly become more common in clinical practice, with multidrug-resistant (MDR) gram-negative bacteria contributing to prolonged hospital stays, increased healthcare costs, and high mortality rates among adult and pediatric populations. Using complex and challenging real-world cases, this session will present clinical evidence supporting the newer and pipeline antibiotics to treat MDR gram-negative bacterial infections and evaluate recent literature and updates in gram-negative bacterial infection management. Attendees will learn to identify patient-specific risk factors for MDR gram-negative bacterial infections, interpret resistance patterns accurately, and understand the place in therapy of the newer antibiotics to select the most appropriate antibiotic and improve patient outcomes.

This activity is approved for Board-Certified Pediatric Pharmacy Specialist (BCPPS) and Board-Certified Critical Care Pharmacist (BCCCP) recertification credit.